Abbott Laboratories (ABT)
(Delayed Data from NYSE)
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$118.13 USD
+0.50 (0.43%)
Updated Sep 17, 2024 04:01 PM ET
After-Market: $118.13 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
C Value D Growth C Momentum D VGM
Zacks News
Here's Why AbbVie Stock is Good for Your Portfolio's Health
by Zacks Equity Research
Here are six reasons why investing in AbbVie (ABBV) stock is a good decision now.
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Facebook, Amgen, Abbott, Coca-Cola and 3M
Top Stock Reports for Facebook, Amgen & Abbott
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Facebook (FB), Amgen (AMGN), and Abbott (ABT).
Tap Cardiovascular Devices Market Boom With These 3 Stocks
by Sweta Jaiswal
Consider these three stocks in the rapidly-growing cardiovascular devices market.
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
by Zacks Equity Research
Zacks Industry Outlook Highlights: Boston Scientific, Stryker, Medtronic, Abbott and Varian Medical
Boston Scientific Up on Possible Takeover Bid by Stryker
by Zacks Equity Research
Even if Boston Scientific's (BSX) position remains indefinite on a possible sell-off rumor, the company's strategic stance on this might however, swing in its favor for winning a competitive marketing edge.
Bio-Rad Banks on Solid Global Scenario, Competition Rife
by Zacks Equity Research
Bio-Rad (BIO) delivers robust performance, primarily in North America, China and the Asia-Pacific region.
Abbott Launches Afinion 2 Analyzer Rapid Test in the U.S.
by Zacks Equity Research
Abbott's (ABT) recently-launched Afinion 2 analyzer system is likely to boost top-line contributions from the Diagnostic division.
The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Duke, Charter Communications, Abbott, UnitedHealth and Brown-Forman
Abbott Presents Positive Data for AMPLATZER Amulet Device
by Zacks Equity Research
Abbott (ABT) proceeds with initiatives to boost the core Structural Heart division.
Abbott Presents Positive Study Results for Tendyne Device
by Zacks Equity Research
Abbott (ABT) leaves no stone unturned to drive its Structural Heart business.
Abbott Gets FDA Nod for XIENCE Sierra, To Boost Vascular Wing
by Zacks Equity Research
Abbott (ABT) continues with the slew of developments in regards with the XIENCE Sierra coronary stent system.
Cardiovascular Systems Rides on New Products Amid Tight Race
by Zacks Equity Research
Cardiovascular Systems (CSII) gains traction from a strong third-quarter fiscal 2018, witnessing a year-over-year revenue rise at both CAD and PAD businesses.
Why Is Abbott (ABT) Up 2% Since Its Last Earnings Report?
by Zacks Equity Research
Abbott (ABT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Merck vs. Pfizer: Which Stock Looks Better Post Q1 Earnings?
by Zacks Equity Research
Both Merck and Pfizer reported upbeat first-quarter results on May 1
Universal Health (UHS) Q1 Earnings & Revenues Lag Estimates
by Zacks Equity Research
Universal Health (UHS) posts a solid Q1 driven by higher revenues.
Anthem (ANTM) Beats on Q1 Earnings, Raises '18 Guidance
by Zacks Equity Research
Strong performance across segments supports Anthem's (ANTM) first-quarter results.
Centene (CNC) Q1 Earnings & Revenues Top, '18 View Lowered
by Zacks Equity Research
Centene (CNC) delivers strong first-quarter results on the back of significant membership growth.
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Goldman, Abbott, Altria, PayPal and Progressive
Abbott (ABT) Q1 Earnings & Revenues Top, '18 View Retained
by Zacks Equity Research
Abbott (ABT) continues to gain from a strong and consistent EPD as well as a robust Medical Devices performance.
MS, USB, ABT & TXT Leads Q1 Earnings
by Zacks Equity Research
MS, USB, ABT & TXT Leads Q1 Earnings
Q1 Earnings Keep Markets in the Green: MS, USB, ABT & TXT
by Mark Vickery
We are still in the early stages so far, but overall results have been notably better than expected.
Abbott (ABT) Beats on Earnings and Revenues in Q1
by Zacks Equity Research
Abbott (ABT) gains ground on new product launches and delivers strong Q1 results.
5 Amazing Earnings Charts This Week
by Tracey Ryniec
It's not easy to beat the estimate nearly every quarter for years. But these 5 companies are doing it.
Varian Medical (VAR) Q2 Earnings: Is a Surprise in Store?
by Zacks Equity Research
Strong revenue opportunity from various Oncology and Imaging Component products is likely to drive Varian Medical (VAR) in Q2.